BURLINGAME, Calif.--(BUSINESS WIRE)--Neugenesis Corporation announced today that the company has been awarded a multi-million dollar Phase I contract by the Defense Advanced Research Projects Agency (DARPA) to develop expression technologies that will accelerate recombinant protein production for the rapid manufacturing of vaccines and drugs. Neugenesis collaborated on the winning proposal with SRI International, Xcellerex and BioPharm Services.
